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Abstract The gene encoding an aspartic proteinase precursor
(proplasmepsin) from the rodent malaria parasite Plasmodium
berghei has been cloned. Recombinant P. berghei plasmepsin
hydrolysed a synthetic peptide substrate and this cleavage was
prevented by the general aspartic proteinase inhibitor, isovaleryl
pepstatin and by Ro40-4388, a lead compound for the inhibition
of plasmepsins from the human malaria parasite Plasmodium
falciparum. Southern blotting detected only one proplasmepsin
gene in P. berghei. Two plasmepsins have previously been
reported in P. falciparum. Here, we describe two further
proplasmepsin genes from this species. The suitability of P.
berghei as a model for the in vivo evaluation of plasmepsin
inhibitors is discussed.
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1. Introduction
The aspartic proteinases known as plasmepsins have been
o⁄cially recognised by the World Health Organisation as
suitable targets for the design of novel chemotherapeutic com-
pounds for the treatment of malaria [1]. Enzymes of this class
initiate the haemoglobin breakdown pathway that provides
intra-erythrocytic malaria parasites with nutritional resources
[2] and inhibition of their activity results in death of the ma-
larial parasite [3,4]. As drugs are being designed to block the
action of the malarial aspartic proteinases speci¢cally, an es-
sential safety component of the drug development process is
the need for rigorous testing of such compounds for toxicity.
The availability of an animal model, such as the rodent ma-
laria parasite Plasmodium berghei, in which the potency and
toxicity of lead compounds in vivo could be assessed, would
thus be invaluable. In this study, we describe the cloning,
expression and analysis of a plasmepsin from P. berghei and
consider its relationship to its counterpart enzymes from other
Plasmodium species, particularly the most dangerous human
pathogen, Plasmodium falciparum.
2. Materials and methods
2.1. Cloning of the gene encoding the precursor of P. berghei
plasmepsin (PbPM)
A library of HindIII-digested P. berghei genomic DNA cloned into
pUC8 was a kind gift from Dr J. Dalton (Dublin City University). A
clone encoding part of the PbPM sequence was identi¢ed by probing
this library with the P. falciparum proplasmepsin II gene that was
radiolabelled by random primed synthesis using the Megaprime kit
(Amersham International) according to the manufacturer’s instruc-
tions. The sequence of the P. berghei inserted DNA was determined
and was found to correspond to the 3P end of a gene encoding an
aspartic proteinase. In order to clone further sequences 5P to this
initial fragment, a polymerase chain reaction (PCR)-based strategy
was employed. A reverse primer CB33 (gcgagcatgcggatccTTAGTT-
TTTTGCAACTGCAAAACC) was designed from the sequence of
the 3P end of the gene (capital letters) including its stop codon and
which incorporated SphI and BamHI restriction sites (lower case let-
ters) to facilitate subsequent cloning experiments. A degenerate for-
ward primer CB30 (CWKCWAATKTATGGGTNCC) was designed
to correspond to a region of high DNA sequence conservation be-
tween the genes encoding P. falciparum proplasmepsin I and proplas-
mepsin II. The CB30 and CB33 primers were used in a PCR ampli-
¢cation with P. berghei total genomic DNA as template and the
approximately 880 bp product of this reaction was cloned into
pUC18 using the Sureclone PCR cloning kit (Pharmacia). The in-
serted P. berghei sequence was determined and a further speci¢c oli-
gonucleotide (GGTGTACCATCTTTTTCATATG) was designed.
This primer was used in conjunction with the vector-based reverse
primer (CAGGAAACAGCTATGAC) in a PCR reaction to amplify
the 5P end of the proplasmepsin gene from the original, pooled Hin-
dIII library. The resulting 815 bp fragment was cloned using the
Sureclone kit as above and the inserted DNA was sequenced.
2.2. Southern blot analysis
AV1.1 kb fragment released by BamHI digestion from the plasmid
which encodes semi-proplasmepsin I from P. falciparum [3] was radio-
labelled and used as a probe to screen for the presence of proplas-
mepsin genes in P. berghei. Total P. berghei DNA was digested with
the enzymes DraI, SspI, EcoRI and HindIII and fragments were sep-
arated on a 0.8% agarose gel prior to Southern blotting. The blot was
washed under low stringency conditions (2USSC, 55‡C) prior to auto-
radiography.
2.3. Production of wild-type and mutant forms of semi-proPbPM
A segment of the proPbPM gene encoding a truncated form of the
precursor zymogen (semi-proPbPM: the sequence from the codon for
residue 77 in the propart to the stop codon of proPbPM) was ampli-
¢ed from P. berghei total DNA template using the 5P primer CB42
(ccggaattcggaTCCGAATATTTAACAATTCG) and the 3P primer
CB33 above. The ampli¢ed fragment was digested with BamHI,
cloned into pET3a and its sequence was determined to ensure that
no mutations had arisen during PCR. A mutant form carrying a Lys-
Ile substitution at residue 111p in the propart was produced by an
overlapping PCR method as follows. Two complementary oligonu-
cleotide primers were synthesised (spanning nucleotides 487^512 in
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the P. berghei sequence) containing a single nucleotide substitution
(underlined) to introduce the desired mutation. These primers were:
MH5, GAATCATTCATATTATTAAAATCAGG (top strand);
MH6, CCTGATTTTAATAATATGAATGATTC (bottom strand).
PCR was used to amplify the 5P end of the mutant gene using primer
CB42 and the bottom strand primer MH6. The 3P end of the gene was
ampli¢ed using the top strand primer MH5 and CB33. Finally, the
full-length mutated gene was generated in a third PCR in which the
products of the ¢rst two reactions were puri¢ed, mixed and ampli¢ed
using primers CB42 and CB33. The resulting mutant gene was cloned
into the BamHI site of pET3a and the inserted DNA was sequenced
to ensure that the desired mutation had been introduced and that the
rest of the sequence remained unaltered.
Wild-type and mutant constructs were transformed separately into
Escherichia coli BL21(DE3)pLysS. Gene expression and production
and puri¢cation of the two forms of recombinant semi-proPbPM
were carried out essentially as described previously for the counterpart
protein from P. falciparum [3].
2.4. Activation of wild-type and mutant precursors
Wild-type and mutant forms of semi-proPbPM were incubated for
1 h at 37‡C at a variety of pH values. The bu¡ers used were 0.1 M
sodium acetate (pH 3.0^4.4) or 0.1 M sodium acetate (pH 4.5^5.5),
with the ionic strength adjusted where necessary to 0.1 M by the
addition of NaCl. The samples were then subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to determine
whether a reduction in molecular weight, consistent with autoactiva-
tion by removal of the propart, had occurred. Samples were also
prepared for N-terminal sequencing by separation on SDS-PAGE
(12% gel) prior to blotting onto a polyvinylidene di£uoride mem-
brane. The membrane was then stained with amido black and the
appropriate band was excised and subjected to Edman degradation
using a 494 Procise model sequencer equipped with a narrow bore
HPLC system (Perkin Elmer) [5,6].
2.5. Proteinase assays
Aliquots of each form of semi-proPbPM zymogen were mixed with
0.1 volume of 1 M sodium acetate bu¡er, pH 4.6, and incubated at
room temperature for 30 min prior to measurement in duplicate of
proteinase activity using the £uorogenic peptide substrate EDANS-
Asp-Arg-Leu-Glu-Arg-Thr-Phe*Leu-Ser-Phe-Thr-Thr-Asp-Arg-DAB-
SYL at a ¢nal concentration of 0.5 WM in 100 Wl of 100 mM sodium
acetate bu¡er, pH 4.6, in a 96 well microtitre plate. Fluorescence was
monitored (excitation at 350 nm, detection at 560 nm) in a Cyto£uor
2350 plate reader (Millipore AG, Switzerland) after 225 min. Control
reactions were performed using substrate in the absence of enzyme
and the absorbance values were subtracted from those obtained in the
presence of enzyme. Samples were also pre-incubated with the inhib-
itors isovaleryl pepstatin (IVP) or Ro40-4388 [3] (50 WM ¢nal concen-
tration) for 5 min before reactions were started by the addition of the
substrate. Since the substrate was dissolved in 50% (v/v) DMSO and
inhibitor stocks were dissolved in 100% (v/v) DMSO, the concentra-
tion of DMSO in all assays was standardised to a ¢nal concentration
of 1.5% (v/v).
2.6. Molecular modelling of PbPM
A three dimensional model of mature PbPM was constructed, using
the crystal structure of human cathepsin D [7] as the template struc-
ture, on a Silicon Graphics Indy R4600 workstation using Moloc, the
Ho¡mann-La Roche in-house molecular modelling package [8]. The
quality of the model was checked with a program developed by Lue-
thy et al. [9].
2.7. Database searches and sequence alignments
The proPbPM protein sequence was used in BLAST searches [10]
to search various databases for other proplasmepsin sequences. Pre-
liminary sequence data for P. falciparum chromosome 14 were ob-
tained from The Institute for Genomic Research website (www.ti-
gr.org). Sequencing of chromosome 14 was part of the International
Malaria Genome Sequencing Project and was supported by awards
from the Burroughs Wellcome Fund and the U.S. Department of
Defense. Other proplasmepsin sequences (together with the sequences
of zymogens of an aspartic proteinase-like protein, HAP, from P.
falciparum [11] and of an aspartic proteinase from the protozoan
parasite Eimeria acervulina) were derived from the Swiss-Prot and
EMBL databases (Table 1). Sequences were aligned initially using
the Pileup program in the GCG package before minor modi¢cations
were made manually from a knowledge of aspartic proteinase struc-
tures.
3. Results and discussion
3.1. Sequence and activation
The DNA sequence encoding P. berghei proplasmepsin has
been deposited in the EMBL database under accession num-
ber AJ223308 (Table 1). It predicts a protein of 450 amino
acids (Fig. 1) containing all the features typical of an aspartic
proteinase but with a much longer propart (124 residues) than
archetypal zymogens such as pepsinogen (59 amino acids in-
cluding the signal peptide). A truncated form of the P. berghei
zymogen (semi-proPbPM) with a shortened propart, similar in
length to that of pepsinogen, was produced in E. coli. How-
ever, the wild-type form of the truncated precursor did not
undergo autoactivation when incubated over a range of acidic
pH values (results not shown). In order to facilitate autoacti-
vation of semi-proPbPM, it was therefore necessary to intro-
duce a suitable self-processing site between the propart and
the mature enzyme regions of the precursor. The wild-type
protein sequence was changed from Phe(110p)-Lys(111p)-
Leu(112p)-Leu(113p)-Lys(114p) to Phe(110p)-Ile(111p)-Leu-
(112p)-Leu(113p)-Lys(114p) (p denotes that these are propart
residues) in order to introduce an isoleucine residue into the
P2 position of the putative VP2-P1*P1P-P2PV autoactivation
site (nomenclature of Schechter and Berger [12]) since it was
predicted from the model of the PbPM active site that this
would be accommodated more e⁄ciently than the wild-type
lysine. A comparable mutation introduced into semi-proplas-
mepsin I from P. falciparum resulted in successful autoactiva-
Table 1
Database entries used in sequence alignment
Source organism Protein Accession no. Reference
P. berghei ProPbPM AJ223308a This study
P. falciparum Proplasmepsin I X75787a/P39898b [4]
P. falciparum Proplasmepsin II L10740a/P46925b [13]
P. falciparum Proplasmepsin III AL008970a [17]
P. falciparum Proplasmepsin IV Chromosome 14, contig s 138c Unpublished
P. falciparum ProHAP AJ009990a [11]
E. acervulina EaAP Z24676a [14]
The alignment shown in Fig. 1 was generated from sequences for the indicated proteinase using accession numbers for EMBL database, Swiss-
Prot and The Malaria Genome Project contig number.
aEMBL database.
bSwiss-Prot.
cThe Malaria Genome Project contig number.
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Fig. 1. Alignment of the deduced amino acid sequence of the plasmepsins from P. berghei with those of other aspartic proteinases. Sequences
listed in Table 1 were aligned as described in Section 2. The proPbPM sequence is given in full. In the other sequences, spaces indicate identity
to the equivalent residue in proPbPM, hyphens indicate gaps introduced to optimise the alignment. ProPfPM I, II, III and IV = the P. falcipa-
rum proplasmepsins I [4], II [13] and the new proplasmepsins III and IV identi¢ed in this study. ProHAP = the histo-aspartic protein precursor
[11] and EaAP is the precursor of the aspartic proteinase from E. acervulina. The location of the lysine residue 111p that was mutated in semi-
proPbPM is marked with an t. The polyproline loop residues 292^295 (pepsin numbering) are marked with *. Other residues mentioned in the
text are numbered according to the pig pepsin numbering system.
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tion [3]. The mutated semi-proPbPM was found to have an
Mr of 43 kDa on SDS-PAGE under reducing conditions.
The N-terminal sequence determined for this precursor band
was Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-Met-Gly-Arg-GlyV,
which corresponds to the N-terminal leader sequence intro-
duced from the pET3a vector. When aliquots of this protein
were incubated at pH 4.6, the mutant semi-proPbPM exhib-
ited a shift in size from 43 to 37 kDa (Fig. 2). N-terminal
sequencing of the 37 kDa band gave equal amounts of two
overlapping sequences which could be resolved by reference to
the predicted amino acid sequence of proPbPM. The ¢rst,
Leu-Lys-Ser-Gly-Leu-Leu-Lys-Lys-Glu-His-Leu-ThrV (ami-
no acids 113p^124p; Fig. 1), represents cleavage at the in-
tended Leu(112p)*Leu(113p) bond in the mutant activation
sequence (VIle(111p)-Leu(112p)*Leu(113p)-Lys(114p)-
Ser(115p)-Gly(116p)V). The second sequence, Ile-Leu-Leu-
Lys-Ser-Gly-Leu-Leu-Lys-Lys-Glu-HisV is two residues lon-
ger than the ¢rst and indicates that activation had also oc-
curred to an equal extent at another cleavage point created by
the mutation of residue 111p to isoleucine in the sequence
VPhe(110p)*Ile(111p)-Leu(112p)-Leu(113p)-Lys(114p)-Ser-
(115p)-Gly(116p)V.
3.2. Activity of mature PbPM
Wild-type semi-proPbPM was inactive when incubated with
the £uorogenic substrate EDANS-Asp-Arg-Leu-Glu-Arg-Thr-
Phe*Leu-Ser-Phe-Thr-Thr-Asp-Arg-DABSYL both before
and after exposure to acidic conditions (not shown). Similarly,
the Lys111pIle mutant precursor (43 kDa) did not show any
activity against this peptide prior to exposure to the acidic
activation conditions. In contrast, the mature PbPM
(37 kDa) that resulted from autoactivation of mutant semi-
proPbPM readily hydrolysed the £uorogenic substrate (Table
2) and at a rate comparable to that measured previously for
plasmepsin I from P. falciparum (Moon, unpublished). Sub-
strate cleavage was prevented not only by the general aspartic
proteinase inhibitor IVP, but also by the compound Ro40-
4388 (Table 2) which we have reported previously to be able
to kill P. falciparum maintained in human red blood cells in
culture [3]. Thus, the aspartic proteinase from P. berghei ap-
pears to have a susceptibility to inhibition and an activity
which are similar to its counterpart enzyme(s) from the major
human pathogen P. falciparum. On this basis, P. berghei
appears worthy of consideration as a model species for eval-
uation of inhibitor potency and toxicity. However, two plas-
mepsins have been characterised previously from P. falcipa-
rum, plasmepsin I [4] and plasmepsin II [13], together with a
third gene encoding a closely related protein, HAP (which
shares s 60% identity in the mature region with plasmepsin
I and plasmepsin II but lacks one of the active site aspartic
acid residues necessary for the activity of the aspartic protein-
ase class of enzymes [11]). Southern blot analysis of P. berghei
DNA (Fig. 3) revealed only one hybridising band in each lane,
indicating that this parasite species contains only one gene
encoding a proplasmepsin.
Fig. 2. Autoactivation of Lys111pIle mutant semi-proPbPM. Sam-
ples of puri¢ed, recombinant mutant semi-proPbPM were analysed
by SDS-PAGE under reducing conditions before (lane 1) and after
(lane 2) incubation in 0.1 M sodium acetate bu¡er, pH 4.6 for 1 h
at 37‡C.
Table 2
Substrate cleavage and inhibition of the plasmepsin from P. berghei




Samples of mature PbPM were incubated for 225 min at pH 4.6
with EDANS-Asp-Arg-Leu-Glu-Arg-Thr-Phe*Leu-Ser-Phe-Thr-Thr-
Asp-Arg-DABSYL as substrate, either alone or in the presence of
50 WM inhibitors IVP or Ro40-4388 [3].
Fig. 3. Southern blot of P. berghei DNA. Total P. berghei genomic
DNA was cut with the restriction enzymes DraI (D), SspI (S),
EcoRI (E) or HindIII (H) and the products were separated in a
0.8% agarose gel. After transfer, the blot was hybridised with plas-
mepsin I probe DNA and washed as described in Section 2. Marker
sizes are shown in kb.
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3.3. New plasmepsins in P. falciparum
With the realisation that P. berghei contrasts with P. falci-
parum in containing only one aspartic proteinase (-like) gene,
we used the proPbPM sequence in BLAST searches of the
ever-expanding databases derived from the P. falciparum ge-
nome sequencing projects. In this way, we established the
presence of genes encoding two yet further aspartic protein-
ases (plasmepsins III and IV) in P. falciparum.
Fig. 1 shows a multiple alignment of the sequence of
proPbPM with the four aspartic proteinase zymogens from
P. falciparum, in addition to P. falciparum proHAP and the
precursor of an aspartic proteinase from the parasite E. acer-
vulina (accession numbers and references for all sequences are
listed in Table 1). ProPbPM clearly di¡ers from proHAP since
the latter lacks one of the active site Asp residues necessary
for the mechanism of action of an aspartic proteinase [11]. In
addition, proPbPM has only a low level of identity (25%) with
proplasmepsin III. The proplasmepsin III precursor is itself
quite distinct from the other Plasmodium proteins aligned in
Fig. 1 since it has 925% identity to any of the others and has
the sequence VAsp-215-Thr-216-Gly-217V £anking the cat-
alytic Asp(215) residue. In contrast, plasmepsins I, II and IV
and the plasmepsin from P. berghei all have an VAsp-Ser-
GlyV sequence for this hallmark motif (Fig. 1; [4,13]). The
proplasmepsin III sequence is most closely related (42% iden-
tity) to the precursor of an aspartic proteinase from another
apicomplexan parasite, E. acervulina [14]. Both have consid-
erably shorter proparts (V80 residues) than proplasmepsins I,
II, IV and the proPbPM identi¢ed in this study (Fig. 1). They
appear to have a signal peptide, as observed in all vertebrate/
fungal aspartic proteinase precursors [15], whereas the prop-
arts of proplasmepsins I, II and IV and proPbPM all contain
a membrane-spanning stretch of 20 hydrophobic amino acids
(residues 38p^59p) which has been implicated in the type II
membrane anchoring of these zymogens [16]. In addition, in-
spection of the locus of the proplasmepsin III gene within the
completed sequence of chromosome 3 from P. falciparum re-
veals that the coding exons are interrupted by no less than 14
introns. This is in itself uncommon in P. falciparum but is
totally unprecedented with regard to the other aspartic pro-
teinase genes from P. falciparum or P. berghei. These coding
sequences are not interrupted by any introns whatsoever.
In contrast, proplasmepsin IV from P. falciparum appears
to be closely related to the previously identi¢ed proplasmep-
sins I and II and indeed to the proplasmepsin from P. berghei
described in this study (50^55% identity in each case). Dis-
tinction amongst these enzymes is possible, however, by ex-
amination, for example, of the sequence of residues 292^295
(Fig. 1) which has frequently been referred to as the ‘polypro-
line loop’ in vertebrate/fungal aspartic proteinases because of
the predominance of Pro residues at this location in many
enzymes. Plasmepsin II (Fig. 1) has the sequence VFPVPV,
whereas plasmepsin I has VLNKNV containing a basic res-
idue, whilst plasmepsin IV has VIDDNV with two acidic
Asp residues. In the PbPM sequence of VIDANV, there is
only a single acidic residue in this region. Since the polypro-
line loop in£uences the nature of substrate residues accommo-
dated within the S2P and S3P subsites of the active site cleft of
aspartic proteinases, these sequence variations in this region
of plasmepsins I, II, IV and PbPM are likely to confer subtly
di¡erent substrate speci¢cities on each of these enzymes.
Thus, on this basis alone, it is not possible to categorise the
plasmepsin from P. berghei as the direct counterpart of any
one of the P. falciparum proteinases. Furthermore, since the
rodent malaria parasite appears to have only one gene encod-
ing a proplasmepsin, it seems that P. berghei does not repre-
sent an ideal model system for the in vivo analysis of inhib-
itors targeted against the battery of plasmepsins in the
dangerous human pathogen, P. falciparum. A study of the
localisation of PbPM and elucidation of the expression pat-
terns of its gene throughout the life-cycle stages of the rodent
parasite will be necessary to determine whether PbPM is able
by itself to ful¢l all of the functions that apparently require
the attentions of four closely related plasmepsins (and HAP)
within P. falciparum. From the results presented here, P. ber-
ghei may have a di¡erent dependence on aspartic proteinases
from its most deadly human counterpart, P. falciparum.
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